Immunotherapy News and Research

Latest Immunotherapy News and Research

Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial

Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial

31 Jan 2011
EVP of Advaxis' Science & Operations moderates Live Cancer Vaccines panel discussion

EVP of Advaxis' Science & Operations moderates Live Cancer Vaccines panel discussion

29 Jan 2011
Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

24 Jan 2011
Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer

Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer

24 Jan 2011
Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis

Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis

24 Jan 2011
CRI, Oncovir sign new investment agreement to produce immunological stimulant

CRI, Oncovir sign new investment agreement to produce immunological stimulant

24 Jan 2011
CVAF completes new investment agreement with Oncovir for production of Hiltonol

CVAF completes new investment agreement with Oncovir for production of Hiltonol

21 Jan 2011
Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

21 Jan 2011
Advaxis receives DSMB approval to complete dosing in first leg of ADXS11-001 cervical dysplasia clinical trial

Advaxis receives DSMB approval to complete dosing in first leg of ADXS11-001 cervical dysplasia clinical trial

14 Jan 2011
Positive results from Allovectin-7 Phase 3 trial in patients with metastatic melanoma

Positive results from Allovectin-7 Phase 3 trial in patients with metastatic melanoma

11 Jan 2011
Dendreon provides U.S. commercialization and European strategy updates for PROVENGE

Dendreon provides U.S. commercialization and European strategy updates for PROVENGE

7 Jan 2011
Cell Medica enters EBV-associated cancer research collaboration with CAGT and Baylor College of Medicine

Cell Medica enters EBV-associated cancer research collaboration with CAGT and Baylor College of Medicine

7 Jan 2011
Generex, Antigen Express and RXi report positive research data from active immunotherapy collaboration

Generex, Antigen Express and RXi report positive research data from active immunotherapy collaboration

7 Jan 2011
Antigenics announces name change to Agenus

Antigenics announces name change to Agenus

6 Jan 2011
Opexa completes meetings with FDA regarding planned development program for Tovaxin

Opexa completes meetings with FDA regarding planned development program for Tovaxin

6 Jan 2011
Unique vaccine produces long-lasting anti-cocaine immunity in mice

Unique vaccine produces long-lasting anti-cocaine immunity in mice

5 Jan 2011
DBV Technologies secures $25.5 million in Series C financing round

DBV Technologies secures $25.5 million in Series C financing round

5 Jan 2011
Researchers develop unique vaccine that produces long-lasting anti-cocaine immunity in mice

Researchers develop unique vaccine that produces long-lasting anti-cocaine immunity in mice

5 Jan 2011
Immunitor reports positive safety imm01 clinical trial against tuberculosis

Immunitor reports positive safety imm01 clinical trial against tuberculosis

30 Dec 2010
CEL-SCI initiates Multikine Phase III trail for head and neck cancer

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

29 Dec 2010

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback